The importance of serotonin and noradrenaline in anxiety

International Journal of Psychiatry in Clinical Practice

Volumn 11, Issue SUPPL. 2, 2007, Pages 16-23

  Blier, Pierre ^a   Mansari, Mostafa El ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Anxiety disorders; Brain; Citalopram; Escitalopram; Noradrenaline; Obsessive compulsive disorder (OCD); Serotonin (5 HT)

Indexed keywords

CITALOPRAM; ESCITALOPRAM; NORADRENALIN; PAROXETINE; SEROTONIN;

ARTICLE; CELL ACTIVATION; FRONTAL CORTEX; HUMAN; NERVE CELL; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; ORBITAL CORTEX; PRIORITY JOURNAL;

EID: 34249031225     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.1080/13651500701388310     Document Type: Article

References (25)

1. Goodman WK, Price LH, Delgado PL, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 1990;47(6):577-85.
2. Jenike MA. Obsessive-compulsive disorder: efficacy of specific treatments as assessed by controlled trials. Psychopharmacol Bull 1993;29(4):487-99.
3. Pigott TA, Seay SM. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 1999;60(2):101-6.
4. Fallon BA, Mathew SJ. Biological therapies for obsessive-compulsive disorder. J Psychiatr Pract 2000;6(3):113-28.
5. Dhillon S, Scott LJ, Plosker GL. Escitalopram: a review of its use in the management of anxiety disorders. CNS Drugs 2006;20(9):763-90.
6. Lechin F, van der Dijs B, Hernandez-Adrian G. Dorsal raphe vs. median raphe serotonergic antagonism. Anatomical, physiological, behavioral, neuroendocrinological, neuropharmacological and clinical evidences: relevance for neuropharmacological therapy. Prog Neuropsychopharmacol Biol Psychiatry 2006;30(4):565-85.
7. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002;71(4):533-54.
8. Pineyro G, Blier P. Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev 1999;51(3):533-91.
9. Waugh J, Goa KL. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs 2003;17(5):343-62.
10. Sanchez C. The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram. Basic Clin Pharmacol Toxicol 2006;99(2):91-5.
11. Chen F, Larsen MB, Sanchez C, Wiborg O. The S-enantiomer of R, S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 2005;15(2):193-8.
12. Sanchez C, Bogeso KP, Ebert B, Reines EH, Braestrup C. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berlin) 2004;174(2):163-76.
13. El Mansari M, Sanchez C, Chouvet G, Renaud B, Haddjeri N. Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. Neuropsychopharmacol 2005;30(7):1269-77.
14. Hensler JG. Regulation of 5-HT1A receptor function in brain following agonist or antidepressant administration. Life Sci 2003;72(15):1665-82.
15. Riiad M, Zimmer L, Rbah L, Watkins KC, Hamon M, Descarries L. Acute treatment with the antidepressant fluoxetine internalizes 5-HT1A autoreceptors and reduces the in vivo binding of the PET radioligand [18F]MPPF in the nucleus raphe dorsalis of rats. J Neurosci 2004;24(23):5420-6.
16. Mork A, Kreilgaard M, Sanchez C. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 2003;45(2):167-73.
17. Sanchez C, Gruca P, Papp M. R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Behav Pharmacol 2003;14(5-6):465-70.
18. El Mansari M, Bouchard C, Blier P. Alteration of serotonin release in the guinea pig orbito-frontal cortex by selective serotonin reuptake inhibitors. Relevance to treatment of obsessive-compulsive disorder. Neuropsychopharmacol 1995;13(2):117-27.
19. El Mansari M, Blier P. Responsiveness of 5-HT(1A) and 5-HT2 receptors in the rat orbitofrontal cortex after long-term serotonin reuptake inhibition. J Psychiatry Neurosci 2005;30(4):268-74.
20. Bergqvist PB, Bouchard C, Blier P. Effect of long-term administration of antidepressant treatments on serotonin release in brain regions involved in obsessive-compulsive disorder. Biol Psychiatry 1999;45(2):164-74.
21. Blier P. Crosstalk between the norepinephrine and serotonin systems and its role in the antidepressant response. J Psychiatry Neurosci 2001;26(Suppl):S3-10.
22. Szabo ST, deMontigny C, Blier P. Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors. Int J Neuropsychopharmacol 2000;3(1):1-11.
23. Charney DS, Heninger GR. Abnormal regulation of noradrenergic function in panic disorders. Effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 1986;43(11):1042-54.
24. Coplan JD, Papp LA, Pine D, et al. Clinical improvement with fluoxetine therapy and noradrenergic function in patients with panic disorder. Arch Gen Psychiatry 1997;54(7):643-8.
25. Dremencov E, El Mansari M, Blier P. Noradrenergic augmentation of escitalopram response by risperidone: electrophysiologic studies in the rat brain. Biol Psychiatry 2007;61(5):671-8.